Osband M E, Lavin P T, Babayan R K, Graham S, Lamm D L, Parker B, Sawczuk I, Ross S, Krane R J
Joint Clinical Immunotherapy Program, Boston University School of Medicine, Massachusetts.
Lancet. 1990 Apr 28;335(8696):994-8. doi: 10.1016/0140-6736(90)91064-h.
To assess the value of autolymphocyte therapy (ALT) in the treatment of metastatic renal-cell carcinoma, 90 patients were randomised to receive every month for six months oral cimetidine plus an infusion of autologous peripheral blood lymphocytes activated in vitro by a previously generated autologous lymphokine mixture, or cimetidine alone. The median follow-up was 15 months. Survival time for the autolymphocyte group was approximately 2.5 times that for the cimetidine group (p = 0.008). Patients who had greater than 500 pg interleukin-1 (IL-1) per ml autologous lymphokine mixture had a six-fold survival advantage over those with less than 500 pg/ml (p less than 0.00005). Men treated with ALT had a four-fold survival advantage (p = 0.001) over men who received cimetidine only. Infusion of the cultured autolymphocytes was accompanied by mild, self-limited fever in 11 of the 45 ALT patients, and by only one instance in which fever was accompanied by tachypnoea and hypotension.
为评估自体淋巴细胞疗法（ALT）在转移性肾细胞癌治疗中的价值，90例患者被随机分组，一组连续6个月每月接受口服西咪替丁加输注经先前制备的自体淋巴因子混合物体外激活的自体外周血淋巴细胞，另一组仅接受西咪替丁治疗。中位随访时间为15个月。自体淋巴细胞组的生存时间约为西咪替丁组的2.5倍（p = 0.008）。每毫升自体淋巴因子混合物中白细胞介素-1（IL-1）含量大于500 pg的患者，其生存优势是含量低于500 pg/ml患者的6倍（p < 0.00005）。接受ALT治疗的男性患者比仅接受西咪替丁治疗的男性患者有4倍的生存优势（p = 0.001）。45例接受ALT治疗的患者中有11例在输注培养的自体淋巴细胞时伴有轻度、自限性发热，仅有1例发热伴有呼吸急促和低血压。
